<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00290238</url>
  </required_header>
  <id_info>
    <org_study_id>RSMED-K011702-PNT02</org_study_id>
    <nct_id>NCT00290238</nct_id>
  </id_info>
  <brief_title>Percutaneous Neuromodulation Therapy (PNT) With Chronic Low Back Pain Patients</brief_title>
  <official_title>Percutaneous Neuromodulation Therapy With Chronic Low Back Pain Patients With or Without Lower Extremity Pain - A Randomized, Controlled, Parallel Groups Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RS Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RS Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the benefits of Percutaneous Neuromodulation Therapy
      when compared to a reference sham treatment in the treatment of patients who have undergone
      surgical intervention for chronic low back pain with or without a radiating lower extremity
      pain component.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow recruitment and high dropout rates
  </why_stopped>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Time-Averaged Pain Intensity Visual Analog Scale (VAS) Score</measure>
    <time_frame>Time-averaged from the first available observation to the last available observation (12 months for completed subjects)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Expenditure Per Day on All Lower Back Pain Related Interventions</measure>
    <time_frame>Baseline, Month 01, Month 02, Month 04, Month 06, Month 08, Month 10, Month 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Low Back Pain</condition>
  <arm_group>
    <arm_group_label>PNT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TENS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vertis Percutaneous Neuromodulation Therapy (PNT)</intervention_name>
    <description>Ten PNT sessions in eleven weeks
On average, one PNT session per week
Ten lumbar Safeguide electrodes (three centimeters in length) deployed per lumbar montage
Forty-five minutes of electrical stimulation for each session
Electrical stimulation parameters:
Continuous 50 Hz current
Charge-balanced, biphasic (each phase is 200 microsec), rectangular waveform
Intensity to subject's tolerance for ten minutes then increased to a mildly uncomfortable level</description>
    <arm_group_label>PNT</arm_group_label>
    <other_name>PNT</other_name>
    <other_name>Vertis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcutaneous Electrical Nerve Stimulation (TENS)</intervention_name>
    <description>Ten TENS sessions in eleven weeks
On average, one TENS session per week
Four 2-inch (5.1 centimeters) diameter pads applied per TENS lumbar montage
Forty-five minutes of electrical stimulation for each session
Electrical stimulation parameters:
Current at 2 Hz—low frequency
Pulse trains delivered as asymmetric, biphasic, square waveform current, with pulse width lasting 20 microsec
Intensity titrated according to subject's sensory threshold
To maintain blinding, the treating physician or clinician will check on the subject after 10 minutes and dial the channels down just prior to the point of turning off the device.</description>
    <arm_group_label>TENS</arm_group_label>
    <other_name>TENS</other_name>
    <other_name>Transcutaneous electrical nerve stimulation</other_name>
    <other_name>surface stimulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Low back pain for at least 6 months

          -  If lower extremity pain present, must be present for at least 3 months

          -  Visual analog scale (VAS) score for low back pain at least 50 out of 100

          -  Lumbar or lumbosacral surgical intervention without pain relief

          -  Central sensitization symptoms

          -  Agrees to follow randomized treatment plan

          -  18 years of age or older

          -  Signed informed consent form

        Exclusion Criteria:

          -  Significant change to low back or lower extremity pain within 4 weeks prior to
             enrollment

          -  Nociceptive and/or neuropathic pain symptoms in the spine due to structural and/or
             mechanical instabilities

          -  Three or more lumbar or lumbosacral surgical interventions; one or more surgical
             interventions in areas other than lumbar or lumbosacral spine

          -  Three or more lumbar vertebral segments fused

          -  Lumbar or lumbosacral surgical intervention in last 9 months; areas other than lumbar
             or lumbosacral in last 12 months

          -  Any additional surgical intervention required 3 months post-enrollment

          -  Symptoms consistent with sympathetically-maintained pain

          -  Evidence of serious neurological deficits or impairments

          -  Significant changes in pain medications within 4 weeks prior to enrollment

          -  Psychosocial issues that conflict with valid reporting by patient

          -  Prior treatment with percutaneous electrical stimulation or sensitivity to electrical
             stimulation

          -  Current use of another electrical stimulation device for low back or lower extremity
             pain

          -  Current enrollment in another clinical trial within the last 30 days

          -  Current or prior malignancy or cancer

          -  Serious or uncontrolled systemic illness

          -  Body mass index (BMI) greater than 40

          -  Pregnant or intends to become pregnant during the study

          -  Implanted medical device

          -  Relationship with study staff

          -  Unable to attend study office visits or complete study measures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Carroll</last_name>
    <role>Study Director</role>
    <affiliation>RS Medical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD Pain Research Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Prospective Outcome Studies</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>03027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mossberg Research Group</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pain Specialists of Southern Oregon</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuropsychiatric Pain Medicine Association of Tennessee</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37922</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physical Medicine &amp; Rehabilitation Center</name>
      <address>
        <city>Seymour</city>
        <state>Tennessee</state>
        <zip>37865</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Back Institute - Denton</name>
      <address>
        <city>Denton</city>
        <state>Texas</state>
        <zip>76208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Back Institute CRO</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>White PF, Ghoname EA, Ahmed HE, Hamza MA, Craig WF, Vakharia AS. The effect of montage on the analgesic response to percutaneous neuromodulation therapy. Anesth Analg. 2001 Feb;92(2):483-7.</citation>
    <PMID>11159255</PMID>
  </reference>
  <reference>
    <citation>Ghoname ES, Craig WF, White PF, Ahmed HE, Hamza MA, Gajraj NM, Vakharia AS, Noe CE. The effect of stimulus frequency on the analgesic response to percutaneous electrical nerve stimulation in patients with chronic low back pain. Anesth Analg. 1999 Apr;88(4):841-6.</citation>
    <PMID>10195535</PMID>
  </reference>
  <reference>
    <citation>White PF, Craig WF, Vakharia AS, Ghoname E, Ahmed HE, Hamza MA. Percutaneous neuromodulation therapy: does the location of electrical stimulation effect the acute analgesic response? Anesth Analg. 2000 Oct;91(4):949-54.</citation>
    <PMID>11004055</PMID>
  </reference>
  <reference>
    <citation>Seroussi RE, Gliner BE, et. al. Effectiveness of Percutaneous Neuromodulation Therapy for Patients with Chronic and Severe Low Back Pain. Pain Practice 3(1) 22-30, 2003</citation>
  </reference>
  <reference>
    <citation>Borg-Stein J, Seroussi RE, Gomba L, Meleger A, Schmitt S, Leep E, Glassman JH, Revord J, Condon J, Bensen E, Fitzthum JE, Fowler BC, Gliner BE, Firlik AD. Safety and efficacy of percutaneous neuromodulation therapy in the management of subacute radiating low back pain. Pain Pract. 2003 Jun;3(2):125-34.</citation>
    <PMID>17163911</PMID>
  </reference>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2006</study_first_submitted>
  <study_first_submitted_qc>February 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2006</study_first_posted>
  <results_first_submitted>November 25, 2008</results_first_submitted>
  <results_first_submitted_qc>February 6, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 9, 2009</results_first_posted>
  <last_update_submitted>May 8, 2009</last_update_submitted>
  <last_update_submitted_qc>May 8, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2009</last_update_posted>
  <responsible_party>
    <name_title>Vice President of Research and Development</name_title>
    <organization>RS Medical</organization>
  </responsible_party>
  <keyword>Chronic Low Back Pain</keyword>
  <keyword>Lower Extremity Pain</keyword>
  <keyword>Central Sensitization</keyword>
  <keyword>Percutaneous Neuromodulation Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Percutaneous Neuromodulation Therapy (PNT)</title>
          <description>Active/test group receiving 10 Percutaneous Neuromodulation Therapy (PNT) sessions of 45 minutes each over 11 weeks. PNT delivers 50 Hz current in a charge-balanced, biphasic, rectangular waveform.</description>
        </group>
        <group group_id="P2">
          <title>Transcutaneous Electrical Nerve Stimulation (TENS)</title>
          <description>Sham comparator group receiving 10 TENS sessions of 45 minutes each over 11 weeks. Delivered 2 Hz pulse trains as asymmetric, biphasic, square waves with pulse width of 20 microseconds.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="65">One subject had an invalid birth date and was excluded from the Age Categorical counts.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study terminated</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Percutaneous Neuromodulation Therapy (PNT)</title>
          <description>Active/test group receiving 10 Percutaneous Neuromodulation Therapy (PNT) sessions of 45 minutes each over 11 weeks. PNT delivers 50 Hz current in a charge-balanced, biphasic, rectangular waveform.</description>
        </group>
        <group group_id="B2">
          <title>Transcutaneous Electrical Nerve Stimulation (TENS)</title>
          <description>Sham comparator group receiving 10 TENS sessions of 45 minutes each over 11 weeks. Delivered 2 Hz pulse trains as asymmetric, biphasic, square waves with pulse width of 20 microseconds.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="57"/>
            <count group_id="B2" value="65"/>
            <count group_id="B3" value="122"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>One subject had an invalid birth date and was excluded from the Age Categorical counts.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.7" spread="15.1"/>
                    <measurement group_id="B2" value="55.9" spread="11.0"/>
                    <measurement group_id="B3" value="54.8" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Time-averaged Pain Intensity Visual Analog Scale (VAS) Score</title>
        <description>Visual analog scale (VAS) for pain (100mm line with &quot;0/No pain&quot; on the left and &quot;100/Worst pain imaginable&quot; on the right). Subjects drew vertical line to indicate pain. Time-averaged method accounts for time between visits by dividing area beneath the score curve by time between first and last available visits.</description>
        <time_frame>Time-averaged from the first available observation to the last available observation (12 months for completed subjects)</time_frame>
        <population>Analysis population was intention to treat (ITT), excluding subjects who had no follow-up (after the initial 10-week treatment phase) data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Neuromodulation Therapy (PNT)</title>
            <description>Active/test group receiving 10 Percutaneous Neuromodulation Therapy (PNT) sessions of 45 minutes each over 11 weeks. PNT delivers 50 Hz current in a charge-balanced, biphasic, rectangular waveform.</description>
          </group>
          <group group_id="O2">
            <title>Transcutaneous Electrical Nerve Stimulation (TENS)</title>
            <description>Sham comparator group receiving 10 TENS sessions of 45 minutes each over 11 weeks. Delivered 2 Hz pulse trains as asymmetric, biphasic, square waves with pulse width of 20 microseconds.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Time-averaged Pain Intensity Visual Analog Scale (VAS) Score</title>
          <description>Visual analog scale (VAS) for pain (100mm line with &quot;0/No pain&quot; on the left and &quot;100/Worst pain imaginable&quot; on the right). Subjects drew vertical line to indicate pain. Time-averaged method accounts for time between visits by dividing area beneath the score curve by time between first and last available visits.</description>
          <population>Analysis population was intention to treat (ITT), excluding subjects who had no follow-up (after the initial 10-week treatment phase) data available.</population>
          <units>mm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Back pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.9" spread="3.1" lower_limit="29.5" upper_limit="89.5"/>
                    <measurement group_id="O2" value="-11.7" spread="2.7" lower_limit="35.5" upper_limit="88.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Radiating leg/buttock pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.8" spread="3.2"/>
                    <measurement group_id="O2" value="-9.8" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Expenditure Per Day on All Lower Back Pain Related Interventions</title>
        <description>Expenditures were assessed by patient report at each visit. Interventions were coded to Current Procedural Terminology (CPT) 2008; costs were derived from Medicare, Managed Care, and Workers’ Comp fees. Costs for providers assume 30 minutes at returning patient rate. Drug costs were coded to a dictionary extrapolated from 2008 market prices.</description>
        <time_frame>Baseline, Month 01, Month 02, Month 04, Month 06, Month 08, Month 10, Month 12</time_frame>
        <population>Analysis population was intention to treat (ITT).</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Neuromodulation Therapy (PNT)</title>
            <description>Active/test group receiving 10 Percutaneous Neuromodulation Therapy (PNT) sessions of 45 minutes each over 11 weeks. PNT delivers 50 Hz current in a charge-balanced, biphasic, rectangular waveform.</description>
          </group>
          <group group_id="O2">
            <title>Transcutaneous Electrical Nerve Stimulation (TENS)</title>
            <description>Sham comparator group receiving 10 TENS sessions of 45 minutes each over 11 weeks. Delivered 2 Hz pulse trains as asymmetric, biphasic, square waves with pulse width of 20 microseconds.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Expenditure Per Day on All Lower Back Pain Related Interventions</title>
          <description>Expenditures were assessed by patient report at each visit. Interventions were coded to Current Procedural Terminology (CPT) 2008; costs were derived from Medicare, Managed Care, and Workers’ Comp fees. Costs for providers assume 30 minutes at returning patient rate. Drug costs were coded to a dictionary extrapolated from 2008 market prices.</description>
          <population>Analysis population was intention to treat (ITT).</population>
          <units>Dollars</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.97" lower_limit="0" upper_limit="77.20"/>
                    <measurement group_id="O2" value="5.30" lower_limit="0" upper_limit="118.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Percutaneous Neuromodulation Therapy (PNT)</title>
          <description>Active/test group receiving 10 Percutaneous Neuromodulation Therapy (PNT) sessions of 45 minutes each over 11 weeks. PNT delivers 50 Hz current in a charge-balanced, biphasic, rectangular waveform.</description>
        </group>
        <group group_id="E2">
          <title>Transcutaneous Electrical Nerve Stimulation (TENS)</title>
          <description>Sham comparator group receiving 10 TENS sessions of 45 minutes each over 11 weeks. Delivered 2 Hz pulse trains as asymmetric, biphasic, square waves with pulse width of 20 microseconds.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3"/>
                <counts group_id="E2" subjects_affected="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruise/abrasion/fracture/other injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Low back pain (serious events)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29"/>
                <counts group_id="E2" subjects_affected="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Virus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Urinary/bladder infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruise/abrasion/fracture/other injury</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Drug reaction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Low back pain (non-serious events)</sub_title>
                <counts group_id="E1" events="44" subjects_affected="17" subjects_at_risk="57"/>
                <counts group_id="E2" events="57" subjects_affected="22" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Leg/buttock/hip or radiating pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="57"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Arm/shoulder pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If the PI expects to participate in the publication or presentation of data generated in the performance of the study, any reports, abstracts, manuscripts, or other presentation materials shall be submitted to the sponsor for review prior to submission for publication or presentation. The sponsor shall have 30 calendar days to respond with any requested revisions in order to protect the sponsor's confidential information.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research Manager</name_or_title>
      <organization>RS Medical</organization>
      <phone>360-891-7299</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

